Qsox1 as an anti-neoplastic drug target
Patent Number: US20160122765
Executive Summary:
The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.
General Description:
Pancreatic ductal adenocarcinoma (PDA) is a disease that carries a poor prognosis. It is often detected in stage III resulting in an unresectable tumor at the time of diagnosis. However, even if pancreatic cancer is surgically resected in stage I or II, it may recur at a metastatic site. Currently, patients diagnosed with pancreatic ductal adenocarcinoma have less than a 5% chance of surviving past five years.
Breast adenocarcinoma is the most common cancer diagnosed in women throughout the world. In 2012, an estimated 226,870 new cases of invasive breast cancer are expected to occur among US women, and an estimated 39,510 breast cancer deaths.
The present invention provides methods for tumor treatment, comprising administering to a subject having pancreatic tumor an amount effective of an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1) expression and/or activity, or a pharmaceutically acceptable salt thereof, to treat the tumor. The inhibitor of QSOX1 is selected from the group consisting of anti-QSOX1 antibodies, QSOX1-binding aptamers, QSOX1 antisense oligonucleotides, QSOX1 siRNA, and QSOX1 shRNA. The present invention also provides isolated nucleic acids, comprising or consisting of antisense, siRNA, miRNA, and/or shRNA molecules having a nucleic acid sequence that is perfectly complementary at least 10 contiguous nucleotides of QSOX1.
Strengths:
Patent Status:
Priority date: 2010-09-20
Filing date: 2015-09-09
Publication date: 2016-05-05
Publications:
1. Hanavan PD, Borges CR, Katchman BA, Faigel DO, Ho TH, Ma CT, Sergienko EA, Meurice N, Petit JL, Lake DF. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cell lines. Oncotarget (2015).
2. Antwi K, Hanavan P, Myers CE, Ruiz Y, Thompson EJ, and Lake DF. Identification of an MHC-binding Peptidome from Pancreas and Breast Cancer Cell Lines. Molecular Immunology (2009).
3. Antwi K, Hostetter G, Demeure MJ, Decker GA, Ruiz Y, Sielaff T, Koep L and Lake DF. Analysis of Human Plasma Peptidome Reveals Potential Biomarker for Pancreatic Cancer. Journal of Proteome Research (2009).
Inventor Bio: Douglas Lake
https://sols.asu.edu/people/douglas-lake
Executive Summary:
The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.
- Invention Type: Therapeutic
- Patent Status: Patent pending
- Patent Link: https://patents.google.com/patent/US20160122765/
- Research Institute: Arizona State University
- Disease Focus: Cancer and related diseases
- Basis of Invention: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors
- How it works: Near-infrared light will trigger a conformational change of the lipid bilayer to release the encapsulated therapeutic agent to the desired location
- Lead Challenge Inventor: Douglas Lake
- Inventors: Douglas Lake, Benjamin Katchman, Deborah Fass
- Development Stage: Pre-clinical, in vitro and in vivo assays data available
- Novelty:
- Target tumors that over-expresses QSOX1 with specific inhibitors to inhibit this tumor cell growth
- Clinical Applications:
- Treatment for pancreatic ductal cancer and breast cancer
General Description:
Pancreatic ductal adenocarcinoma (PDA) is a disease that carries a poor prognosis. It is often detected in stage III resulting in an unresectable tumor at the time of diagnosis. However, even if pancreatic cancer is surgically resected in stage I or II, it may recur at a metastatic site. Currently, patients diagnosed with pancreatic ductal adenocarcinoma have less than a 5% chance of surviving past five years.
Breast adenocarcinoma is the most common cancer diagnosed in women throughout the world. In 2012, an estimated 226,870 new cases of invasive breast cancer are expected to occur among US women, and an estimated 39,510 breast cancer deaths.
The present invention provides methods for tumor treatment, comprising administering to a subject having pancreatic tumor an amount effective of an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1) expression and/or activity, or a pharmaceutically acceptable salt thereof, to treat the tumor. The inhibitor of QSOX1 is selected from the group consisting of anti-QSOX1 antibodies, QSOX1-binding aptamers, QSOX1 antisense oligonucleotides, QSOX1 siRNA, and QSOX1 shRNA. The present invention also provides isolated nucleic acids, comprising or consisting of antisense, siRNA, miRNA, and/or shRNA molecules having a nucleic acid sequence that is perfectly complementary at least 10 contiguous nucleotides of QSOX1.
Strengths:
- Unique target QSOX1 and potential effective treatment for pancreatic cancer with very low survival rate
Patent Status:
Priority date: 2010-09-20
Filing date: 2015-09-09
Publication date: 2016-05-05
Publications:
1. Hanavan PD, Borges CR, Katchman BA, Faigel DO, Ho TH, Ma CT, Sergienko EA, Meurice N, Petit JL, Lake DF. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cell lines. Oncotarget (2015).
2. Antwi K, Hanavan P, Myers CE, Ruiz Y, Thompson EJ, and Lake DF. Identification of an MHC-binding Peptidome from Pancreas and Breast Cancer Cell Lines. Molecular Immunology (2009).
3. Antwi K, Hostetter G, Demeure MJ, Decker GA, Ruiz Y, Sielaff T, Koep L and Lake DF. Analysis of Human Plasma Peptidome Reveals Potential Biomarker for Pancreatic Cancer. Journal of Proteome Research (2009).
Inventor Bio: Douglas Lake
https://sols.asu.edu/people/douglas-lake
